Actively Recruiting
Phase 2 Study of CRD-4730 in Adults With Catecholaminergic Polymorphic Ventricular Tachycardia Evaluating Safety and Effects With Repeated Doses in a Placebo-Controlled Crossover Design
Led by Cardurion Pharmaceuticals, Inc. · Updated on 2026-07-09
12
Participants Needed
12
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating CRD-4730, an oral drug, in a Phase 2 clinical trial involving adults with Catecholaminergic Polymorphic Ventricular Tachycardia CPVT. This study aims to assess the safety, tolerability, pharmacokinetics PK, and pharmacodynamics PD of CRD-4730. Participants will be part of a randomized, double-blind, placebo-controlled crossover study to better understand how CRD-4730 affects CPVT symptoms and treatment responses. Participants will be randomly assigned to one of three sequences in a 3-period crossover design. Each participant will receive two different doses of CRD-4730 and one matching placebo dose in a random order. The study includes multiple dosing periods where participants take tablets of CRD-4730 or placebo, allowing researchers to compare the effects and tolerability of different doses against placebo. During the trial, participants will undergo various assessments to monitor safety, drug levels, and effects on their condition from baseline to Day 101. The study involves close monitoring of heart function and other health measures, with outcome evaluations occurring at multiple timepoints. This will help researchers understand how the drug behaves in the body and its impact on CPVT symptoms, with the trial lasting several months to complete all study periods and follow-ups.
CONDITIONS
Brief Title
A Phase 2 Study of CRD-4730 in CPVT
Research Team
C
Cardurion
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
